אנהרטו - Enhertu: הבדלים בין גרסאות

HER2-Positive Metastatic Breast CancerENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either:• in the metastatic setting, or• in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.HER2-Low Metastatic Breast CancerENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ orIHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed diseaserecurrence during or within 6 months of completing adjuvant chemotherapyUnresectable or Metastatic HER2-Mutant Non-Small Cell Lung CancerENHERTU is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an approved test, and who have received a prior systemic therapy. Locally Advanced or Metastatic Gastric CancerENHERTU is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.